Evolving Landscape of Oral Therapies for Psoriasis

The discussion focuses on the evolving landscape of oral therapies for psoriasis, highlighting advancements from traditional treatments like methotrexate to newer options, such as apremilast and the recently approved TIK2 inhibitor, ducravacitinib. Apremilast, a PDE4 inhibitor, is noted for its FDA approval for patients with plaque psoriasis regardless of severity, effective in mild to moderate cases, but often accompanied by gastrointestinal side effects like nausea and diarrhea. The presentation emphasizes the potential of novel PDE4 inhibitors, such as ME3183, which demonstrate improved efficacy while still posing similar tolerability challenges. Ducravacitinib shows promise with sustained long-term efficacy and minimal GI side effects, providing a valuable alternative. Additionally, ongoing developments in TIK2 inhibitors and an oral IL-23 receptor inhibitor mark exciting possibilities for targeted oral therapies. Other compounds, such as DC8O6, mimic biologics in their action against IL-17A. The presentation concludes by expressing optimism for future oral therapies, emphasizing their convenience, specificity, and effectiveness in treating psoriasis, with the hope that advancements will continue to expand treatment options for patients.